2026-02-18
CoQ10 and Mitochondrial Function: Age-Related Decline and Clinical Evidence
CoQ10 declines with age and statin exposure. Human evidence is strongest in heart failure and statin-associated muscle symptoms, while prevention use in healthy adults remains less certain.
2026-02-18
Depression and Mood Decline in Aging: Evidence-Based Approaches
Late-life depression is underdiagnosed and undertreated. This article covers the neurobiological drivers of mood decline in aging and the best-evidenced interventions.
2026-02-18
Eleuthero (Siberian Ginseng): Adaptogen Evidence, Fatigue, and Comparison with Rhodiola
Eleuthero (Eleutherococcus senticosus) is one of the most studied adaptogens, with Soviet-era and modern research on fatigue, immune function, and physical performance. Evidence quality is moderate; its benefit profile overlaps with rhodiola but with a distinct safety profile.
2026-02-17
NAD+ Precursor Supplementation and Cognitive Fatigue: Mechanism and Human Evidence
NAD+ precursors reliably elevate blood NAD+ in humans and activate mitochondrial energy pathways. Whether this translates to clinically meaningful reductions in cognitive fatigue requires larger, longer trials.
2026-02-14
Supplement Cycling Protocols: Rapamycin, Senolytics, and Adaptogens — Evidence for Intermittent Use
Not all supplements should be taken daily. Rapamycin is typically dosed weekly to preserve mTOR signaling windows. Senolytics (dasatinib + quercetin, fisetin) are used in short intermittent bursts. Even some adaptogens are cycled to prevent tolerance. This article maps the rationale and evidence for each.